topoisomerases


Also found in: Dictionary, Medical.

topoisomerases

[¦tä·pō·ī′säm·ə‚rās·əz]
(biochemistry)
Any of a group of enzymes capable of relaxing, unwinding, unpackaging, or changing the degree of supercoiling of deoxyribonucleic acid fiber.
Mentioned in ?
References in periodicals archive ?
Level of DNA topoisomerase IIa mRNA predicts the treatment response of relapsed acute leukemic patients.
This study was performed to elucidate the role of a topoisomerase I inhibitor (topotecan) in the treatment of chemoresistant ovarian cancer-initiating cells.
Zylka said that a temporary exposure to a topoisomerase inhibitor in utero has the potential to have a long-lasting effect on the brain, by affecting critical periods of brain development.
The goal of this study was to determine the resistance mechanism to fluoroquinolones in Salmonella isolates and investigate the association of quinolone resistance with mutations in the genes encoding for DNA gyrase and topoisomerase IV of S.
Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery.
10) Utilizing advanced molecular technology, the research team that conducted these studies evaluated possible inhibitory effects of grape cell culture extract and subfractions on human DNA topoisomerase II catalytic activity.
We can test potential new drugs against topoisomerases as well as help discover new inhibitors as a first step to developing brand new drugs.
Many of the antitumour antibiotics can work as topoisomerase inhibitors.
The QRDR within topoisomerases contains hotspots for mutations around the active site, which are associated with raised MIC values for fluoroquinolones (10).
Besides his administrative and teaching activities, DiGate is known for his research on the role of DNA topoisomerases in DNA replication and the design and synthesis of topoisomerase inhibitors.
Cambridge, MA; 617-761-6996) and Xenova Group, plc (Slough, England; 44 (0) 1753 706600), have signed a license agreement for the development and North American commercialization of Xenova's novel compounds, which have a unique mechanism of action including dual inhibition of topoisomerases I and II, for the treatment of solid tumors in cancer.